Abstract: Valemetostat (also known as DS-3201 or EZHARMIA) is a novel, orally bioavailable, selective dual inhibitor of the enhancer of zeste homolog 1 and 2 (EZH1/2) proteins, which are catalytic subunits of the polycomb repressive complex 2 (PRC2). By preventing the tri-methylation of histone H3 at lysine 27 (H3K27), valemetostat reverses the epigenetic silencing of tumor suppressor genes implicated in various hematological malignancies. While it received its first global approval in Japan in 2022 for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma (ATL), valemetostat has demonstrated significant preclinical and clinical efficacy against B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). This review synthesizes the current literature on valemetostat, detailing its pharmacological activity, molecular mechanism of action, structural properties, current clinical limitations, and future therapeutic perspectives in the context of B-cell lymphoma and other cancers.
1. Introduction
Epigenetic regulators of gene expression have emerged as a prominent target class for cancer therapy, with numerous epigenetic therapies currently in clinical development [1]. The polycomb repressive complex 2 (PRC2) is a key epigenetic regulator that catalyzes the mono-, di-, and trimethylation of Histone 3 at Lysine 27 (H3K27), leading to chromatin compaction and gene silencing [2]. The enhancer of zeste homolog 1 and 2 (EZH1 and EZH2) serve as the alternative catalytic subunits of PRC2 [1][2]. Epigenomic studies have demonstrated that inappropriate H3K27me3 deposition—often resulting from gain-of-function mutations or the overexpression of EZH2—is a critical determinant of abnormal transcriptomes in various cancers, including non-Hodgkin lymphomas (NHL) such as B-cell lymphomas [1].
Valemetostat tosilate (valemetostat; EZHARMIA; DS-3201) is an orally administered, selective dual inhibitor of both wild-type and mutated forms of EZH1 and EZH2 developed by Daiichi Sankyo [1][2]. It received its first regulatory approval in Japan in September 2022 for the treatment of patients with relapsed or refractory (R/R) adult T-cell leukemia/lymphoma (ATL) [1]. Given its potent ability to target excessive EZH1 and EZH2 activities, valemetostat is currently being extensively investigated for its therapeutic potential in B-cell malignancies and other solid tumors [1][2].
2. Pharmacological Activity
Valemetostat exhibits potent antiproliferative effects across various hematological cancer cell lines, regardless of EZH2 mutation status [1]. In the context of B-cell lymphoma, in vitro studies have shown that valemetostat possesses strong antiproliferative activity against the activated B-cell-like (ABC) and germinal center B-cell-like (GCB) subtypes of diffuse large B-cell lymphoma (DLBCL) [1][2]. It induces apoptosis in DLBCL cell lines irrespective of the subtype and suppresses the expression levels of the BCL6 protein, a key oncogene in B-cell lymphoma [1].
In vivo, valemetostat has demonstrated significant efficacy in DLBCL tumor xenograft models. Once-daily oral administration of valemetostat at 100 mg/kg resulted in almost complete tumor regression without associated weight loss, while a lower dosage of 25 mg/kg effectively slowed tumor growth [1]. Furthermore, valemetostat has shown synergistic effects when combined with standard-of-care treatments for NHL and DLBCL both in vitro and in vivo [1].
Pharmacokinetically, valemetostat is highly protein-bound (94–95%), predominantly binding to human a1 acidic glycoprotein. It is primarily metabolized by the CYP3A enzyme and is mainly excreted in the feces (79.8% of total radioactivity) [1]. Clinical trials have demonstrated its efficacy in R/R NHL, and specific Phase 2 trials (such as the VALYM trial) are actively evaluating its efficacy in R/R B-cell lymphomas [1][2].
3. Molecular Mechanism of Action
Valemetostat functions as a potent, selective dual inhibitor of the EZH1 and EZH2 methyltransferases [1][2]. In cell-free enzymatic assays, it inhibits the methylation activity of these enzymes with an IC50 of 10.0 nM for EZH1 and 6.0 nM for EZH2 [1]. By inhibiting these catalytic subunits of the PRC2 complex, valemetostat suppresses the tri-methylation of the lysine 27 residue on histone H3 (H3K27me3) [1].
The reduction in global H3K27me3 levels alters gene expression patterns associated with cancer pathways, leading to the reactivation of epigenetically silenced tumor suppressor genes and a subsequent decrease in the proliferation of EZH1/2-expressing cancer cells [1]. A critical mechanistic advantage of valemetostat over selective EZH2 inhibitors (such as tazemetostat) is its dual targeting capability. Preclinical research indicates that when cells are exposed to selective EZH2 inhibition, EZH1 can compensate for the loss of EZH2, leading to ectopic EZH1/2 accumulation and a partial reversal of the reactivated gene expression [1][2]. In contrast, treatment with valemetostat is not associated with ectopic enrichment of EZH1/2, ensuring that H3K27me3 levels remain persistently depleted [1].
4. Structure-Activity Relationship (SAR)
Chemically, valemetostat tosilate is designated as (2R)-7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide mono(4-methylbenzenesulfonate) [1]. It belongs to several chemical classes, including amides, amines, benzodioxoles, chlorinated hydrocarbons, cyclohexanes, and pyridones [1].
While detailed functional group substitutions are not exhaustively mapped in the provided literature, valemetostat is characterized as an S-adenosylmethionine (SAM)-competitive inhibitor [2]. This means it competes with the methyl donor SAM for binding within the PRC2 complex. Its structural design allows it to effectively bind and inhibit both EZH1 and EZH2, which provides a broader and more robust epigenetic blockade compared to highly selective EZH2 inhibitors like GSK126 or tazemetostat. This dual-inhibition structural profile grants valemetostat greater efficacy against potential drug resistance mechanisms that rely on EZH1 compensatory activity [2].
5. Current Limitations
Despite its therapeutic promise, the clinical application of valemetostat is accompanied by several limitations and safety concerns:
- Adverse Events: The safety profile of valemetostat includes significant hematological and non-hematological toxicities. The most frequent adverse reactions include thrombocytopenia (occurring in up to 80% of patients), anemia (44%), alopecia (40.5%), dysgeusia (40.5%), neutropenia, leukopenia, and lymphopenia [1][2]. Severe myelosuppression requires careful monitoring and potential dose interruptions or reductions [1].
- Drug-Drug Interactions: Because valemetostat is predominantly metabolized by CYP3A and is a substrate/inhibitor of P-glycoprotein (P-gp), its pharmacokinetics are highly susceptible to co-administered drugs. Co-administration with strong CYP3A or P-gp inhibitors (e.g., itraconazole) significantly increases valemetostat exposure, necessitating dose reductions. Conversely, strong CYP3A inducers (e.g., rifampicin) drastically decrease its exposure [1].
- Food Effects: Food has a significant impact on the drug's absorption. High-fat and low-fat meals reduce the geometric mean Cmax and AUC values by approximately 50% compared to fasting conditions. Consequently, valemetostat must be administered on an empty stomach [1].
- Severe Risks: Embryofetal toxicity and teratogenicity have been reported in animal studies. Furthermore, secondary malignancies, such as chronic myelomonocytic leukemia and precursor B-cell acute leukemia, have been reported in clinical studies [1].
6. Future Perspectives
The future clinical trajectory for valemetostat is highly focused on expanding its indications within B-cell lymphomas and overcoming resistance mechanisms. Currently, multiple clinical trials are ongoing to evaluate its efficacy in aggressive B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Hodgkin lymphoma [2]. For instance, the Phase 2 VALYM trial is specifically assessing valemetostat in patients with R/R B-cell lymphoma [1][2].
To enhance therapeutic outcomes and combat potential resistance, valemetostat is being investigated in combination therapies. Ongoing trials are testing it in conjunction with agents such as Rituximab, Lenalidomide, Atezolizumab, Obinutuzumab, and Tafasitamab [2]. Additionally, its application is being broadened beyond hematological malignancies into solid tumors, with trials exploring its use in metastatic breast cancer, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and urothelial cancers [1][2].
Future research must also prioritize the identification of predictive biomarkers for PRC2 inhibitor responsiveness. Establishing biomarkers that correlate with valemetostat efficacy and resistance will be crucial for optimizing patient stratification, improving clinical decision-making, and personalizing therapeutic interventions in B-cell lymphoma and other cancers [2].
